Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.
about
Pharmacogenetic study of deferasirox, an iron chelating agentDeferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overloadGuidelines for the Standard Monitoring of Patients With Thalassemia: Report of the Thalassemia Longitudinal Cohort.Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET.GFR in Patients with β-Thalassemia Major.The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan.Treating thalassemia major-related iron overload: the role of deferiprone.An update on iron chelation therapyToward optimizing the use of deferasirox: potential benefits of combined use with deferoxamineEfficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.Beta thalassemia major in a developing country: epidemiological, clinical and evolutionary aspects.Combined chelation therapy with deferasirox and deferoxamine in thalassemia.Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia.Nitric oxide-mediated regulation of ferroportin-1 controls macrophage iron homeostasis and immune function in Salmonella infectionDeferasirox: appraisal of safety and efficacy in long-term therapy.Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion.Efficacy of Deferasirox as an Oral Iron Chelator in Paediatric Thalassaemia Patients.Disorders associated with systemic or local iron overload: from pathophysiology to clinical practice.Deferasirox: pharmacokinetics and clinical experience.Renal aspects of thalassaemia a changing paradigm.Current approach to iron chelation in children.Clinical pharmacology of deferasirox.Deferasirox nephrotoxicity-the knowns and unknowns.Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.Deferasirox for managing iron overload in people with thalassaemia.Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?Fanconi Syndrome Secondary to Deferasirox in Diamond-Blackfan Anemia: Case Series and Recommendations for Early Diagnosis.Morbidities in non-transfusion-dependent thalassemia.Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment.Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients.Efficacy and adverse effects of oral chelating therapy (deferasirox) in multi-transfused Pakistani children with β-thalassemia majorIron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis.L-mimosine and dimethyloxaloylglycine decrease plasminogen activation in periodontal fibroblasts.Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine.Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST).Deferasirox-induced renal impairment in children: an increasing concern for pediatricians.Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.Iron-chelation therapy with oral chelators in patients with thalassemia major.
P2860
Q28533457-37369E0B-D9C5-4B45-B881-35B431AD8E90Q33411923-2398D4B4-4DE8-428F-82DE-38AB19643AEDQ35813192-AB31833F-CB5A-4D25-A033-9C69113AFC37Q35881019-DA66BEE3-F6BD-4186-8570-335587C2EF54Q35906193-D9D71E5F-E3A7-4EC3-8C3C-BBE2F3048252Q35922753-9C284D9F-3D19-49CC-9A33-A0E8962A6248Q36158835-C9E4E029-D2B4-4C0A-99CF-00E87BF8D5B0Q36344669-60B24BFE-0D94-4CCA-AD0F-27DDF7FA50AFQ36393446-4FA0CBAC-95AB-4A62-B974-D483F2356861Q36498403-CE67C7F3-F1D7-4212-BC4B-A9CA1B088239Q36524624-3C2EA899-1A04-45AD-980F-6AD9775F2F70Q36555894-D8B0F1E9-C56F-4C4F-8503-7136EA6299D7Q36670257-CB3C49B6-1A9A-42C6-BBB3-A25F7901D76EQ36771647-2BC4E5FF-B707-48A8-A915-E32C10E0B261Q36822684-3B83C869-3B74-4CED-9AB1-A0FEF4D98CFCQ37095523-3528FC91-A91C-4214-A934-0D5F83598507Q37528626-92A6C970-2234-4BF2-8FDA-7FBF6A9B993EQ37734245-62D384DF-874E-46EE-990E-9AC6A9B841C7Q37928941-C5DFC9AA-1600-4543-99C3-2D5866E9082BQ37969225-54F9A752-A7CF-440C-9900-1C27D1E051E7Q38017754-7F9F803D-243B-45BB-815D-BDB5AECCA72BQ38197269-D3C599EE-70D7-409B-BA53-3EE4A2CD74F3Q38226394-8A4330E8-F8D1-4F94-A641-874D4D17FA48Q38232442-808AA146-E60C-4DE0-B4D4-B8A48B1AF563Q38421726-3F2BCF37-3FA9-4138-9813-CD91768D5FFCQ38624033-99CBD360-2A3B-40A2-9C2E-726863DC3053Q38650293-7A1EF8D4-A32C-438E-B631-7BFFEBF50FABQ38727988-E369EF6E-7F88-4C44-AE9F-D0687A170832Q38809109-5E6931B8-D9C5-42DF-8B33-CC6EFBEE9D1EQ38836177-1B64DE74-74E2-429D-ACDA-6FD8A16B6E2AQ40499884-34FFC75F-C47D-4672-9DBE-BB209181E139Q40657471-D5F3B1B7-3C01-4D4D-979D-FE621A4D5D67Q40762243-8E7B2885-A4FE-494E-868A-9A510AF08D35Q40892218-50732C2F-9994-4280-BB66-9D03C25A7E58Q42440906-1514CC11-5A79-4104-9DF6-63F1A0025480Q42446307-C866F59F-7DE1-4674-87BB-D65EA768D872Q44113037-8D5DF601-7C3F-4279-AD5E-832B87BC65FCQ44476390-48933845-AB28-4CF7-94A8-D4F2E87AD1E0Q44645350-0D809B1E-A2CE-4F58-A37B-D028C2D68AA0Q45753026-35BF8884-606A-438E-A405-7E82DFF4A0F3
P2860
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Iron chelation with deferasiro ...... ety during 5 years' follow-up.
@ast
Iron chelation with deferasiro ...... ety during 5 years' follow-up.
@en
Iron chelation with deferasiro ...... ety during 5 years' follow-up.
@nl
type
label
Iron chelation with deferasiro ...... ety during 5 years' follow-up.
@ast
Iron chelation with deferasiro ...... ety during 5 years' follow-up.
@en
Iron chelation with deferasiro ...... ety during 5 years' follow-up.
@nl
prefLabel
Iron chelation with deferasiro ...... ety during 5 years' follow-up.
@ast
Iron chelation with deferasiro ...... ety during 5 years' follow-up.
@en
Iron chelation with deferasiro ...... ety during 5 years' follow-up.
@nl
P2093
P50
P1433
P1476
Iron chelation with deferasiro ...... fety during 5 years' follow-up
@en
P2093
Alan Cohen
Antonio Piga
Antonis Kattamis
Duran Canatan
Guillermo Drelichman
Joan Clark
Leyla Agaoglu
Louis Griffel
Marcello Capra
Marina Economou
P304
P356
10.1182/BLOOD-2010-11-316646
P407
P577
2011-05-31T00:00:00Z